Improving Lung Cancer Drug Development
Tony S.K. Mok, BMSc, MD, FRCPC, from the Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.
Tony S.K. Mok, BMSc, MD, FRCPC, Professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.
Mok says in order to move forward, multiple parties such as pharmaceutical industries, academic institutions, and the FDA have to make changes.
As an example, Mok says, the FDA should look into how it registers drugs because the current practice of demanding a companion diagnostic may actually be slowing down the development of the drug.
Mok also suggests making changes to the pharmaceutical industry by having external tribunals advise pharmaceutical companies on which drugs to develop rather than wasting money by trying to develop many drugs.
Clinical Pearls
- Pharmaceutical industries, academic institutions, and the FDA are among those that need to make changes in order to move lung cancer treatment forward
- The FDA should reevaluate how it registers drugs so it does not slow down the development of the drug
- Pharmaceutical companies should have external tribunals to choose which drugs to develop in order to save money
MARIPOSA Trial Shows PFS Benefit With or Without CNS Disease in NSCLC
December 24th 2024During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small cell lung cancer in the first article of a 2-part series.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
